Articles tagged with Breast Cancer
Researchers at Marshall University found that tart cherry consumption reduced mean pain levels by 34.7% compared to a placebo group, with no impact on the effectiveness of aromatase inhibitor treatments for non-metastatic breast cancer patients.
A novel radiopharmaceutical has proven effective in identifying nearly 30 types of malignant tumors with high uptake and image contrast. The tracer targets cancer-associated fibroblasts, which can contribute up to 90% of a tumor's mass.
Researchers have developed DNA nanorobots that recognize and bind to HER2 on breast cancer cells, targeting them for destruction. The nanorobots, consisting of a tetrahedral framework nucleic acid with an attached aptamer, persist in the bloodstream longer than free aptamers and selectively kill only HER2-positive cell lines.
A study found that listening to music at home reduced symptom severity, pain intensity, and fatigue in breast cancer patients. Music therapy also reduced physical and mental fatigue instantly.
A large study published in Radiology found that breast MRI screening for breast cancer survivors leads to higher cancer detection rates, but also results in more unnecessary biopsies. The study analyzed data from over 13,000 women and found no significant differences in sensitivity between breast MRI and mammography.
A UCLA-led study found that combining hormone therapy with the drug ribociclib significantly improved overall survival in premenopausal women with advanced hormone-receptor positive breast cancer. The study showed a 70% survival rate after 42 months compared to 46% for those receiving only hormone therapy.
The study found that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. PBI participants reported less fatigue and were rated more convenient, but experienced slightly poorer cosmesis compared to WBI.
A nationwide survey of 487 women found that nearly two-thirds of breast cancer patients are unaware of surgical options that can minimize scarring. The study also revealed that many patients experience negative impacts from their scars, including feelings of self-consciousness and restricted clothing choices.
A pre-specified secondary analysis of the TAILORx trial found that assessing a woman's recurrence risk based on classic clinical features adds prognostic information complementary to the 21-gene Recurrence Score test. This integration may help identify young women who can forego chemotherapy and those who may benefit from more effectiv...
The NRG GOG 0261 clinical trial shows that paclitaxel plus carboplatin is not inferior to paclitaxel plus ifosfamide in treating women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary. The treatment improved overall survival and progression-free survival outcomes.
Scientists at VCU Massey Cancer Center identified key biological pathways regulating tumor cell spread to vital organs. They discovered the SRC signaling pathway is highly activated in breast cancer metastases, warranting targeted therapies.
The MONALEESA-7 Phase III trial found that adding ribociclib to hormone therapy significantly improved overall survival in premenopausal patients with advanced HR+ breast cancer, with a 29% lower risk of death. The combination was well-tolerated, with no new side effects emerging.
A novel protocol combining intensive chemotherapy, radiation therapy and blood-pressure drug losartan has allowed complete removal of tumors in 61% of participants with locally advanced pancreatic cancer. The treatment significantly improved survival rates and was found to activate immune system pathways.
A new clinical calculator, CTS5, can accurately identify patients at a significantly low risk of their breast cancer returning. This allows them to avoid unnecessary hormone therapy for five years, reducing side effects and psychological burden. The algorithm was tested on 2428 non-trial patients and confirmed its prognostic value.
The latest Annual Report to the Nation on Cancer finds that overall cancer death rates continue to decline in the US. However, a special section reveals a different picture for adults ages 20-49, with higher incidence and mortality among women than men.
A new study conducted by Vanderbilt University found that bioimpedance spectroscopy (BIS) is more effective than traditional tape measures in assessing the risk of developing lymphedema after breast cancer surgery. The technology reduces rates of progression by approximately 10%, a clinically meaningful improvement.
SWOG researchers present numerous high-impact trials at ASCO, focusing on symptom control, survivorship, and quality of care. Studies explore the effectiveness of text messaging for medication adherence in breast cancer patients and investigate gender disparities in severe adverse events among chemotherapy recipients.
A new study found that states that expanded Medicaid saw larger increases in colorectal cancer screening, with an additional 236,573 people screened. The study suggests that Medicaid expansion can improve cancer screening rates among low-income adults.
A study published in JNCI Cancer Spectrum found that diets high in soy foods are associated with a decreased risk of osteoporotic bone fractures in pre-menopausal breast cancer survivors. Soy intake was linked to a 77% reduced risk of fractures, particularly among younger women.
A clinical trial at the University of Cincinnati is investigating the use of targeted proton radiation in early-stage breast cancer. The study aims to evaluate the effectiveness and cosmetic outcomes of this treatment, as well as its side effects and cancer recurrence rates.
Researchers from FAU Harbor Branch Oceanographic Institute are investigating the use of marine natural compounds as potential treatments for triple negative breast cancers. They plan to identify clinically active compounds that could revolutionize treatment regimens and improve survival rates.
Researchers analyzed large volumes of genomic data to determine better research models to fight breast cancer's spread. They found substantial differences between lab-created cell lines and actual advanced tumor samples, with some cell lines showing little genomic similarities to patient tumor samples.
A new blood biopsy technique allows for comprehensive genetic profiling of cancer cells, capturing variation among cells within a single patient. This improves treatment monitoring and targeting by identifying genes active in cancer cells and tracking their response to therapy.
A large Dutch study found that transgender women using hormone treatment have an increased risk of breast cancer, while trans men have a lower risk. The absolute risk is still relatively low and sufficient for current screening guidelines.
A Brazilian research team developed a new strategy to slow the growth of triple negative breast cancer cells by cutting them off from two major food sources: fatty acids and glutamine. The study found that inhibiting both metabolic pathways slowed the growth and migration of resistant TNBC cells.
A study found that cancer screening rates decrease as the day goes on for patients seen later in the day. Decision fatigue and overwhelmed clinicians may contribute to this trend, leading to lower completion rates for screenings like mammograms and colonoscopies.
The FRAX tool accurately determines fracture risk for women with breast cancer treated with aromatase inhibitors when combined with bone mineral density measurements. However, using the tool alone without bone mineral density can lead to overestimation of fracture risk.
The American Cancer Society aims to lower overall cancer mortality 40% between 2015 and 2035, primarily through reducing risk factors like smoking and excess body weight. The goal is based on applying favorable cancer mortality trends among college graduates to the entire population.
A new AI-based method predicts an individual woman's likelihood of being diagnosed with breast cancer using deep learning and full-resolution mammograms. The model outperforms traditional methods in risk discrimination across different races, ages, and family histories.
A retrospective database review of 28 MRI examinations with new suspicious findings found that nearly all were benign, with only a small percentage being proven malignant.
A study led by Vanderbilt University Medical Center's Sheila Ridner found bioimpedance spectroscopy to be more accurate than a tape measure in identifying women at risk of developing lymphedema. The technology reduced rates of progression by approximately 10%, a clinically meaningful improvement.
A study found that BI-RADS 3 lesions in baseline vs non-baseline high-risk screening MRI exams have different cancer yields, with lower rates in baseline exams. Most cancers diagnosed on follow-up are early stage and detected at or before the 6-month mark.
Researchers found that activin B and ALK7 expressed by cancer cells form a barrier that prevents tumor formation and metastasis. The 'barrier' triggers apoptosis in cancer cells, but can be evaded by downregulating activin B or ALK7.
A study published in Developmental Cell suggests that pairing YAP/TAZ inhibitors with another drug, such as trametinib, may extend their benefit to patients. The researchers found that YAP/TAZ promotes growth by regulating glucose metabolism in cancer cells.
Researchers at the University of Chicago discover that obesity reprograms immune cells in breasts to promote tumor formation in triple-negative breast cancers. Obesity promotes inflammation through metabolically-activated macrophages, which fuel tumorigenesis and encourage tumor growth.
Johns Hopkins Medicine researchers have created a 3D image-based model of tumor behavior that captures the complexity of cancer growth. The model uses high-quality imaging data and mathematical formulas to represent blood flow, oxygenation, and structural changes within tumors.
Researchers develop nanobodies that home in on ECM proteins surrounding cancer cells, allowing for early detection and treatment of tumors. The technique has shown promise in imaging and delivering therapeutic treatments to tumors.
Researchers have identified a gene mutation in prostate cancer that is linked to poor survival and increased relapse rates. The study found that men with this mutation are more than three times as likely to die and nearly seven times as likely to relapse on standard treatments.
A study found that clinicians over-order imaging for breast pain, despite a weak correlation with breast cancer. Most respondents (72%) believe there is no strong link between breast pain and breast cancer.
Research analyzed rates of brain metastases in elderly patients with breast cancer, lung cancer, and melanoma. The study found that these cancers carry a significant risk of developing brain metastases later in life, with varying rates among primary cancer types.
A Mayo Clinic study shows that less-invasive mastectomy is a safe option for more patients, including those with locally advanced cancer or surgical complication risk factors. The procedure's complications declined significantly between 2009 and 2017, and reconstruction success rates were high at one year after surgery.
Researchers discovered that tumors subvert endothelial cells' ability to form new blood vessels, using microRNA to control gene expression. Delivering this microRNA to endothelial cells in mice slowed tumor growth and reduced blood vessel formation.
Researchers found that omitting chemotherapy in HER2 positive metastatic breast cancer can significantly shorten progression-free survival but not overall survival. The PERNETTA trial suggests that targeted therapy alone may be safe for patients with low-to-intermediate tumour burden.
A new Australian study aims to develop a framework for effective care to reduce cardiovascular disease in breast cancer survivors. The two-year project will create an integrated model of care, embedding cardiovascular risk management into breast cancer treatment.
A high intake of phenolic acids associated with a healthy diet is linked to a decreased risk of postmenopausal breast cancer. The study found that women who consumed the most hydroxycinnamic acids, particularly chlorogenic acids found in coffee and fruits, had a 62% lower risk of developing breast cancer compared to those with low intake.
A new multigene test called EndoPredict has been found to predict chemotherapy benefit in women with hormone receptor-positive, HER2-negative breast cancer. The test was successful in identifying patients who would benefit from chemotherapy and those who could opt out of the treatment.
Patients with advanced HER2-negative breast cancer treated with continuous chemotherapy showed improved survival rates and maintained quality of life compared to intermittent scheduling. The study also found that treatment holidays had a negative impact on physical quality of life scores, with a clinically meaningful decline at 24 months.
Studies presented at ESMO Breast Cancer Congress 2019 found that young women with breast cancer tend to have more aggressive tumour subtypes, including triple negative and HER2 positive types. However, proper treatment according to guidelines resulted in good survival rates and local recurrence outcomes.
The global HER2 testing survey reveals major access and affordability issues in low and middle income countries, with some upper middle income countries also affected. The study suggests that governments need better information to set planning priorities for investing in infrastructure, testing, and treatment.
The ESMO Breast Cancer Congress stresses the need for a multidisciplinary approach to patient care, including cardiovascular assessment and nutritional support. A study presented at the congress found that dietary guidelines can lead to weight loss and improved quality of life in breast cancer patients.
A combination of biological markers and genetic changes can predict radiation sensitivity, helping doctors assess patients at risk of side effects. The study found that the time of day when radiotherapy is given can also affect side effects, particularly in breast cancer patients.
Researchers found that combining tumor-selective angiotensin blockers with immune checkpoint blockers significantly improves breast cancer treatment in mouse models. The combination treatment normalizes the tumor microenvironment, inducing changes in gene expression and activating immunosupportive pathways.
Researchers identified six factors associated with increased risk of invasive breast cancer recurrence after ductal carcinoma in situ (DCIS) diagnosis. These factors include African-American race, premenopausal status, and high histological grade. The study's findings aim to reduce overtreatment of low-risk DCIS cases.
Women with early, low-risk hormone-driven breast cancer who receive radiotherapy after surgery have a significantly lower risk of recurrence and improved disease-free survival compared to those without radiotherapy. The study found that whole breast irradiation is effective in reducing in-breast recurrences and improving overall survival.
Researchers at Case Western Reserve University have made breakthroughs in identifying who will benefit from chemotherapy using artificial intelligence and radiomics. The studies focused on markers outside the tumor that can indicate treatment response, providing hope for personalized medicine and improved patient outcomes.
A new study suggests that genetic testing, such as Oncotype DX, can help women with early-stage hormone-positive breast cancer avoid chemotherapy and save on treatment costs. The test is estimated to cost around $3,400, and its use could lead to a 8% reduction in chemotherapy costs, resulting in savings of about $338 million annually.
A new study by researchers at the University of Illinois found that combining two cancer drugs, selinexor and 4-OHT, may prevent endocrine resistance in breast tumors. The treatment protocol was more effective than either drug alone in reducing tumor cells' viability.
Researchers at Beth Israel Deaconess Medical Center discover relationship between leucine and tamoxifen resistance in ER+ breast cancer. A diet high in leucine may fuel the growth of breast cancer cells, while reducing leucine levels could be beneficial for patients with ER+ breast cancer.
NRG Oncology received $95 Million in NCI funding for six years, based on exceptional peer review scores. The organization will focus on increasing accrual, supporting young investigators, and raising awareness of clinical cancer research.
Triple negative breast cancer cells can temporarily turn on molecular pathways protecting them from chemotherapy, making them vulnerable to targeted therapy IACS-10759. This discovery offers a new treatment option for resistant TNBC patients.